KartikAnandMD

Oncology • Des Moines, IA

Physician

Join to view full profile

Dr. Anand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Anand's full profile

Already have an account?

Office
1221 Pleasant St
Ste 100
Des Moines, IA 50309
Phone+1 515-282-2921

Fax+1 515-282-1035

Education & Training

Methodist Hospital (Houston)Fellowship, Hematology and Medical Oncology, 2016 - 2019
Louisiana State University School of MedicineResidency, Internal Medicine, 2013 - 2016
Kasturba Medical College ManipalClass of 2012

Certifications & Licensure

IA State Medical License 2023 - 2026
NE State Medical License 2018 - 2026
VA State Medical License 2022 - 2026
LA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Merit Award ASCO Annual Meeting, 2019
Merit Award ASCO (ASCO Immuno Oncology Symposium), 2019

Publications & Presentations

PubMed

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
Ugochi Ebinama, Ajay Sheshadri, Kartik Anand, Iyer Swaminathan
Journal of Immunotherapy and Precision Oncology. 2023-11-01
11 citations
Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.
Kalyan R Chitturi, Ethan A Burns, Ibrahim N Muhsen, Kartik Anand, Barry H Trachtenberg
Current Oncology Reports. 2022-04-01
52 citations
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta
Science Translational Medicine. 2021-12-15

Journal Articles

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
Kartik Anand, Joe Ensor, Barry Trachtenberg, Eric Bernicker, JACC-Cardiooncology

Abstracts/Posters

Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
Kartik Anand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.
2019 ASCO Annual Meeting - 6/1/2019
Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS).
2019 ASCO Annual Meeting - 6/1/2019